Spravato: What It Is, How It Works, Cost, Side Effects & Who Qualifies (2026 Guide)

Important: this article is for information only and is not medical advice. Spravato is a prescription medicine given only in certified clinics — never at home. If you or someone you know is in crisis, call or text 988 (US Suicide and Crisis Lifeline) right now. Talk to a qualified doctor about whether any treatment is right for you.

For roughly a third of people with major depression, standard antidepressants don’t work — not the first one, not the second, sometimes not the fifth. Psychiatrists call this treatment-resistant depression (TRD), and for decades the options after “try another pill” were thin. Then, in 2019, the FDA approved something genuinely new: Spravato.

Spravato (esketamine) is a nasal spray derived from ketamine — the first depression treatment in decades to work through an entirely different brain mechanism, and one that can lift symptoms within hours instead of weeks. But it comes with strict rules: it’s given only under medical supervision, never taken home, and carries real risks. This guide explains what Spravato is, how it works, who qualifies, what a session feels like, side effects, cost and insurance, and how it compares to ketamine infusions — honestly, including the limitations.

What Is Spravato?

Spravato is the brand name for esketamine nasal spray, made by Janssen (Johnson & Johnson Innovative Medicine). Esketamine is the S-enantiomer of ketamine — essentially one “mirror image” half of the ketamine molecule, isolated because it’s the more potent half for depression treatment.

Unlike every standard antidepressant (SSRIs, SNRIs, and older classes), which target serotonin or norepinephrine, Spravato targets the glutamate system — the brain’s most abundant excitatory neurotransmitter. It was the first new-mechanism depression drug approved in decades, and it remains the only esketamine product FDA-approved for depression.

FDA Approval History

The 2025 monotherapy approval is the update most online guides still miss — many still state Spravato “must be taken with an oral antidepressant,” which is now outdated for TRD. One critical limitation has never changed: Spravato’s efficacy in preventing suicide has not been demonstrated, and it does not replace hospitalization or emergency care for someone in acute crisis.

How Spravato Works: The Mechanism in Plain Language

Standard antidepressants adjust serotonin or norepinephrine — a bit like turning up the volume on existing signals. Spravato works on a fundamentally different circuit:

1. NMDA blockade: esketamine blocks NMDA receptors, which normally respond to glutamate.
2. Glutamate surge: paradoxically, this triggers a burst of glutamate release elsewhere in the brain.
3. AMPA activation: the surge stimulates AMPA receptors, a different glutamate receptor type.
4. BDNF release: this cascade releases brain-derived neurotrophic factor — essentially fertilizer for neurons.
5. Neuroplasticity: BDNF promotes synaptogenesis — the growth of new connections between brain cells. Depression is associated with rigid, weakened neural pathways; Spravato helps the brain literally rewire.

This mechanism explains the famous speed difference: while SSRIs typically take 4–8 weeks, Spravato trials showed improvement within 24 hours — one trial measured a 16-point drop on the MADRS depression scale at 24 hours versus 12 points for placebo.

Who Qualifies for Spravato?

Spravato isn’t for everyone with depression. The FDA indications are specific:

• Treatment-resistant depression: adults who have failed at least two prior antidepressant treatments (adequate dose and duration). This is the main indication — as monotherapy or with an oral antidepressant.
• MDD with acute suicidal ideation/behavior: adults with major depressive disorder experiencing depressive symptoms with acute suicidal thoughts or behavior, used with an oral antidepressant.

Just as important is who gets screened out:

• Absolute contraindications: aneurysmal vascular disease, arteriovenous malformation, history of intracerebral hemorrhage, or hypersensitivity to esketamine/ketamine.
• Red flags requiring caution: uncontrolled high blood pressure, significant cardiovascular disease, history of substance or alcohol use disorder, pregnancy or breastfeeding.
• Age: approved for adults; not approved for pediatric patients.

How to Get Spravato: Step by Step

1. Psychiatric evaluation: a psychiatrist confirms the diagnosis and documents the failed prior treatments (usually required for insurance).
2. Medical screening: blood pressure check, cardiovascular history, substance-use screening, pregnancy screening where relevant.
3. Find a REMS-certified clinic: Spravato can only be administered at healthcare settings certified under the FDA’s REMS (Risk Evaluation and Mitigation Strategy) program. Directories of certified clinics exist online.
4. Prior authorization: nearly all insurers require it — your clinic typically handles the paperwork, documenting the two failed antidepressants.
5. Enroll in support programs: Janssen’s Spravato withMe program offers copay assistance and patient support; ask the clinic about enrolling before your first session.

What a Spravato Session Actually Feels Like

Clinical pages describe the logistics; patients describe the experience. Here’s both:

Before: don’t eat for 2 hours beforehand; avoid liquids 30 minutes before. If you use a nasal decongestant spray, take it at least 1 hour before the dose. Arrange a ride — you cannot drive yourself home.

The spray: you self-administer the nasal spray under direct supervision in the clinic — typically 56 mg or 84 mg across devices. It tastes unpleasant; that’s normal and expected.

The next two hours: you stay in the clinic, monitored, for at least 2 hours. This is when the signature effects arrive: dissociation — a sense of detachment from your body or surroundings, described by patients as dreamlike, floaty, or “watching yourself from a slight distance.” It peaks around 40 minutes and typically resolves within 2 hours. Many clinics suggest bringing headphones and a calming playlist; the experience is generally described as strange but not frightening.

After: blood pressure is checked (it often rises temporarily). You need your ride home, and you must not drive or operate machinery until the next day, after a full night’s sleep.

Treatment Schedule

The first month is the most intensive — and the most expensive. Many patients who respond continue maintenance sessions indefinitely; stopping often leads to relapse, a reality worth discussing frankly with your psychiatrist upfront.

Side Effects and Safety

Spravato’s side-effect profile is the reason for the REMS program. Here’s the full picture, from common to serious:

Common side effects

• Dissociation / feeling detached (up to ~61% of patients) — peaks around 40 minutes, resolves within 2 hours
• Dizziness, vertigo, and nausea/vomiting
• Sedation, sleepiness, and lethargy
• Anxiety, headache, and reduced sense of touch/sensation
• Feeling “drunk” or disconnected — impaired judgment and coordination during the session

Medically significant risks

• Blood pressure increase — peaks around 40 minutes and can last up to 4 hours; monitored at every session
• Fainting and impaired consciousness
• Slowed or shallow breathing, especially combined with CNS depressants
• Urinary symptoms with repeated use
• Misuse and dependence — esketamine is a Schedule III controlled substance; misuse can cause serious harm including coma

Drug interactions

• MAOIs and stimulants: increased blood-pressure risk — tell your doctor about everything you take
• CNS depressants (benzodiazepines, opioids, alcohol): increased sedation and respiratory risk

This is why the drug is never dispensed for home use. The entire safety model — supervised administration, 2-hour monitoring, no driving until the next day — exists because these effects are predictable and manageable in a clinic, and dangerous outside one.

Spravato vs. Ketamine Infusions

The most common comparison. They’re related but meaningfully different:

In practice: Spravato is the regulated, insurance-covered path; IV ketamine is the flexible, pay-out-of-pocket path with more prescriber discretion. Some patients try one after the other. “Street ketamine” or DIY use is an entirely different and dangerous matter — not comparable to either medical option.

Cost and Insurance

Spravato is expensive without insurance and manageable with it — but the range is wide:

• Without insurance: roughly $600–$900 per session for the drug alone; all-in session costs of $800–$1,200 plus the clinic visit fee are commonly cited. Monthly totals of $4,700–$6,800 are reported. The first month (8 sessions) is the priciest.
• With insurance: most commercial plans cover Spravato with prior authorization (documenting two failed antidepressants is the key). Medicare Part B covers both the drug and the observation visit. Typical patient responsibility lands around $0–$250 per session, with many patients paying far less through assistance.
• Spravato withMe: Janssen’s copay and patient-assistance program can reduce out-of-pocket costs substantially — enroll before starting if possible.

Navigating prior auth: the paperwork battle is real. Tips that help: make sure your psychiatrist’s notes explicitly document each failed antidepressant (drug, dose, duration); ask the clinic’s prior-auth coordinator — not just the doctor — to manage the submission; and appeal denials, which are frequently overturned with complete records.

Honest Limitations

A responsible guide includes what the marketing doesn’t:

• Effect sizes are modest. In trials, Spravato beat placebo — but placebo also improved substantially (e.g., 20 vs. 16 MADRS points at 4 weeks). It works, but it’s not a miracle.
• Not everyone responds. A meaningful minority of TRD patients don’t improve on esketamine either.
• Maintenance is open-ended. “Every 1–2 weeks indefinitely” is a real lifestyle and financial commitment.
• Suicide prevention not demonstrated. Despite the indication covering depressive symptoms with acute suicidal ideation, the drug hasn’t been shown to prevent suicide itself.
• Long-term data is still maturing. Years of use are newer than decades of SSRI data; questions about very-long-term effects remain.

The Patient Journey: From First Appointment to Maintenance

What does the whole arc look like for a real patient? Roughly this:

• Months before: you’ve tried two or more antidepressants at adequate doses and durations without sufficient response. Your psychiatrist documents each trial carefully — this paper trail is what unlocks insurance.
• Week 0: evaluation, medical screening, prior authorization submitted. Finding a REMS-certified clinic nearby; some patients travel 30–60 minutes each way.
• Weeks 1–4: twice-weekly sessions. Each visit takes about 2.5–3 hours door to door. Many patients describe the first session as the strangest and subsequent ones as routine.
• The assessment point: around week 4, your psychiatrist evaluates response. Clear improvement → step down to weekly. Minimal response → discussion of whether to continue, adjust, or pivot.
• Months 2–3: weekly sessions while life gradually re-expands around the treatment schedule.
• Month 4+: maintenance every 1–2 weeks. For responders, this phase can last months to years, with periodic reassessment of whether to continue.

Spravato for Acute Suicidal Ideation: What the Evidence Shows

The 2020 FDA approval for depressive symptoms in MDD with acute suicidal ideation or behavior deserves careful unpacking, because it’s easily misread.

What the trials showed: esketamine plus an oral antidepressant reduced depressive symptoms rapidly — within hours — in patients presenting with acute suicidal ideation. That speed matters enormously in a crisis setting, where standard antidepressants’ weeks-long lag is a real clinical problem.

What they did not show: that Spravato prevents suicide. The FDA label carries this limitation explicitly. Suicidal ideation is a symptom; suicide is an outcome; the trials weren’t designed to prove the drug changes the outcome. In practice, Spravato is used alongside comprehensive crisis care — hospitalization when indicated, safety planning, close follow-up — not instead of it. If you or someone you love is in acute crisis, emergency care and 988 come first; Spravato is a follow-on conversation with a psychiatrist.

What If Spravato Doesn’t Work?

Not everyone responds — and a good treatment plan includes a Plan B. Options psychiatrists consider after esketamine:

• IV ketamine infusions: off-label but widely used; the prescriber-titrated dosing sometimes helps where fixed-dose esketamine didn’t.
• TMS (transcranial magnetic stimulation): non-invasive brain stimulation, FDA-cleared for TRD, done in daily sessions over several weeks.
• ECT (electroconvulsive therapy): the most effective TRD treatment by the numbers, despite its reputation; modern ECT is far from its cinematic portrayal.
• Newer medications: options like Auvelity (dextromethorphan/bupropion) work through different mechanisms and suit some patients.
• Clinical trials: psychedelic-assisted therapy trials (psilocybin, MDMA-assisted therapy) are recruiting at academic centers.

Non-response to one mechanism says nothing about the next — depression is heterogeneous, and matching treatment to patient remains partly trial and error.

Special Populations: Pregnancy, Breastfeeding, and Older Adults

• Pregnancy: Spravato is not recommended during pregnancy — animal data suggest potential fetal harm. If you’re pregnant or planning pregnancy, discuss alternatives with your psychiatrist and OB-GYN together.
• Breastfeeding: esketamine is present in human milk; breastfeeding is not recommended during treatment.
• Older adults: TRD is common in later life, and esketamine can be effective — but cardiovascular screening is especially important, since blood-pressure effects add to age-related cardiovascular risk. Dosing and monitoring are individualized.
• Adolescents: not FDA-approved for pediatric patients; adolescent TRD is managed through other modalities.

Why a Nasal Spray? The Delivery Story

Why didn’t they just make it a pill? Esketamine taken orally undergoes heavy first-pass metabolism — the liver breaks down most of it before it reaches the brain, making dosing unpredictable. IV infusion works beautifully but requires an IV line, a pump, and a full infusion setup. The nasal spray was the engineering compromise: the nasal mucosa absorbs esketamine quickly and directly into the bloodstream, no IV needed, with bioavailability high enough for reliable fixed dosing (56 mg or 84 mg).

The trade-off is the supervision requirement. Because absorption is fast and the dissociative effects are real, the “spray and stay for 2 hours” model is baked into the drug’s approval — the delivery method and the safety protocol are inseparable.

Spravato Myths vs. Facts

• “It’s just ketamine.” It’s esketamine — one enantiomer of ketamine — in a specific formulation, dose, and supervised protocol. Street ketamine and clinic esketamine share chemistry but nothing else.
• “It works instantly for everyone.” Some feel change within hours; others need weeks; some don’t respond. “Rapid-acting” describes the drug class, not a promise.
• “You can get it prescribed like an antidepressant.” No — it’s never dispensed for home use. Every dose happens in a certified clinic.
• “It’s a cure.” It’s a treatment, usually ongoing. Maintenance sessions and relapse risk are part of the honest picture.
• “The dissociation is the therapy.” Unproven. Whether the subjective experience contributes to the antidepressant effect or is just a side effect of the mechanism is still debated in psychiatry.
• “If SSRIs failed, nothing will work.” False — and exactly the belief Spravato’s existence challenges. Different mechanism, different odds.

Frequently Asked Questions

Does Spravato work for depression?

Clinical trials show it does for many patients with treatment-resistant depression — with improvement sometimes visible within 24 hours, far faster than standard antidepressants. But effect sizes versus placebo are modest, and not everyone responds. It’s a genuine option, not a guaranteed one.

How quickly does Spravato work?

Some patients notice improvement within hours to a day; trials measured significant change at 24 hours. Full assessment of response typically happens over the first month (8 sessions).

Is Spravato covered by insurance?

Usually yes, with prior authorization — most commercial plans cover it once treatment-resistant depression is documented (two failed antidepressants). Medicare Part B covers the drug and the monitoring visit. Janssen’s Spravato withMe program further reduces copays.

Is Spravato the same as ketamine?

Related but not identical. Spravato is esketamine — one enantiomer (mirror-image half) of ketamine — delivered as a supervised nasal spray and FDA-approved for depression. IV ketamine infusions use racemic ketamine, are off-label for depression, and are rarely covered by insurance.

Can I take Spravato at home?

No. It is only administered in REMS-certified healthcare settings under direct supervision, with at least 2 hours of post-dose monitoring. It is never dispensed for home use, and you cannot drive until the next day after sleep.

Conclusion

Spravato represents something rare in psychiatry: a genuinely new mechanism, working on a genuinely faster timeline, for the patients whom existing drugs have failed. The 2025 monotherapy approval made it more accessible, insurance coverage makes it attainable for many, and the supervised-clinic model manages real risks responsibly.

It’s not a miracle, not DIY-able, and not without trade-offs — but for adults with treatment-resistant depression, it’s one of the most important options to discuss with a psychiatrist. If that’s you, bring this guide’s questions to your appointment. And if you’re in crisis right now, skip the research and call or text 988 — help is available 24/7.